Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2017

17.11.2016 | Epidemiology

Trends in cardiac mortality in women with ductal carcinoma in situ

verfasst von: Waqar Haque, Vivek Verma, Anam Haque, E. Brian Butler, Bin S. Teh

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

In certain ductal carcinoma in situ (DCIS) subpopulations, there is no consensus regarding whether to postoperatively irradiate; decisions are often made based on potential risk of cardiac toxicities. Given the utility of Surveillance, Epidemiology, and End Results (SEER) data for studying cardiac mortality in invasive disease, this is the first such study specific for DCIS patients, evaluating trends in cardiac mortality after left-sided radiotherapy (RT).

Methods

The SEER database was queried for patients with DCIS that received RT and had known unilaterality. The central design of this study was to compare cardiac-specific mortality (CSM) between left- and right-sided DCIS patients as stratifying for “older” RT (1973–1982) versus more “modern” RT (1983–1992 or 1993–2002). Survival analysis was performed using Kaplan–Meier methodology and multivariate Cox regression modeling for factors associated with overall survival (OS) and CSS.

Results

Left- and right-sided patients were demographically balanced. CSM was worse for left-sided patients with DCIS diagnosed in 1973–1982 [hazard ratio (HR) 1.295; 95% confidence interval (CI) 1.182–1.420], but not in 1983–1992 (HR 1.022; 95% CI 0.949–1.100) or in 1993–2002 (HR 0.989; 95% CI 0.935–1.046)]. On multivariate analysis, laterality was not associated with OS in either decade. However, left-sided laterality was independently associated with CSM during the 1973–1982 time period, but not the more recent time periods. Examining temporal patterns in the 1973–1982 cohort, cardiac mortality was significantly increased during 10–19 and ≥20 years after diagnosis, but there was no significant increase in cardiac mortality for patients diagnosed up to 10 years after diagnosis.

Conclusions

In the largest such DCIS series to date, left-sided RT was an independent risk factor for increased cardiac mortality from 1973 to 1982, but not after 1983. Using modern RT techniques and maintaining low heart doses, RT may not induce excess CSM in the DCIS population.
Literatur
1.
Zurück zum Zitat Early Breast Cancer Trialists Collaborative Group (EBCTCG), Correa C, McGale P et al (2010) Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr 2010:162–177CrossRef Early Breast Cancer Trialists Collaborative Group (EBCTCG), Correa C, McGale P et al (2010) Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr 2010:162–177CrossRef
2.
Zurück zum Zitat Smith BD (2015) When is good enough really good enough? Defining the role of radiation in low-risk ductal carcinoma in situ. J Clin Oncol 33:686–691CrossRefPubMed Smith BD (2015) When is good enough really good enough? Defining the role of radiation in low-risk ductal carcinoma in situ. J Clin Oncol 33:686–691CrossRefPubMed
3.
Zurück zum Zitat Darby SC, McGale P, Taylor CW, Peto R (2005) Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol 6(8):557–565CrossRefPubMed Darby SC, McGale P, Taylor CW, Peto R (2005) Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol 6(8):557–565CrossRefPubMed
4.
Zurück zum Zitat Darby SC, Ewertz M, McGale P et al (2013) Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 368:987–998CrossRefPubMed Darby SC, Ewertz M, McGale P et al (2013) Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 368:987–998CrossRefPubMed
5.
Zurück zum Zitat Taylor CW, Wang Z, Macaulay E et al (2015) Exposure of the heart in breast cancer radiation therapy: a systematic review of heart doses published during 2003–2013. Int J Radiat Oncol Biol Phys 93:845–853CrossRefPubMed Taylor CW, Wang Z, Macaulay E et al (2015) Exposure of the heart in breast cancer radiation therapy: a systematic review of heart doses published during 2003–2013. Int J Radiat Oncol Biol Phys 93:845–853CrossRefPubMed
6.
Zurück zum Zitat Verma V, Vicini F, Tendulkar RD et al (2016) Role of internal mammary node radiation as a part of modern breast cancer radiation therapy: a systematic review. Int J Radiat Oncol Biol Phys 95:617–631CrossRefPubMed Verma V, Vicini F, Tendulkar RD et al (2016) Role of internal mammary node radiation as a part of modern breast cancer radiation therapy: a systematic review. Int J Radiat Oncol Biol Phys 95:617–631CrossRefPubMed
7.
Zurück zum Zitat Verma V, Beriwal S (2016) Internal mammary node radiation in light of the eortc 22922 and ma.20 trials-what have we really learned? JAMA Oncol 2:992–993CrossRefPubMed Verma V, Beriwal S (2016) Internal mammary node radiation in light of the eortc 22922 and ma.20 trials-what have we really learned? JAMA Oncol 2:992–993CrossRefPubMed
8.
Zurück zum Zitat Giordano SH, Kuo YF, Freeman JL et al (2005) Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst 97:419–424CrossRefPubMedPubMedCentral Giordano SH, Kuo YF, Freeman JL et al (2005) Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst 97:419–424CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Henson KE, McGale P, Taylor C et al (2013) Radiation-related mortality from heart disease and lung cancer more than 20 years after radiotherapy for breast cancer. Br J Cancer 108:179–182CrossRefPubMed Henson KE, McGale P, Taylor C et al (2013) Radiation-related mortality from heart disease and lung cancer more than 20 years after radiotherapy for breast cancer. Br J Cancer 108:179–182CrossRefPubMed
10.
Zurück zum Zitat Park CK, Li X, Starr J, Harris EER (2011) Cardiac morbidity and mortality in women with ductal carcinoma in situ of the breast treated with breast conservation therapy. Breast J 17:470–476CrossRefPubMed Park CK, Li X, Starr J, Harris EER (2011) Cardiac morbidity and mortality in women with ductal carcinoma in situ of the breast treated with breast conservation therapy. Breast J 17:470–476CrossRefPubMed
12.
Zurück zum Zitat Zagar TM, Cardinale DM, Marks LB (2016) Breast cancer therapy-associated cardiovascular disease. Nat Rev Clin Oncol 13:172–184CrossRefPubMed Zagar TM, Cardinale DM, Marks LB (2016) Breast cancer therapy-associated cardiovascular disease. Nat Rev Clin Oncol 13:172–184CrossRefPubMed
13.
Zurück zum Zitat Mast M, Reynders T, Heijenbrok M et al (2016) Tangential IMRT versus TomoTherapy with and without breath-hold in left-sided whole breast irradiation. Acta Oncol 55:240–243CrossRefPubMed Mast M, Reynders T, Heijenbrok M et al (2016) Tangential IMRT versus TomoTherapy with and without breath-hold in left-sided whole breast irradiation. Acta Oncol 55:240–243CrossRefPubMed
14.
Zurück zum Zitat Verma V, Shah C, Mehta MP (2016) Clinical outcomes and toxicity of proton radiotherapy for breast cancer. Clin Breast Cancer 16:145–154CrossRefPubMed Verma V, Shah C, Mehta MP (2016) Clinical outcomes and toxicity of proton radiotherapy for breast cancer. Clin Breast Cancer 16:145–154CrossRefPubMed
Metadaten
Titel
Trends in cardiac mortality in women with ductal carcinoma in situ
verfasst von
Waqar Haque
Vivek Verma
Anam Haque
E. Brian Butler
Bin S. Teh
Publikationsdatum
17.11.2016
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2017
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-016-4045-z

Weitere Artikel der Ausgabe 2/2017

Breast Cancer Research and Treatment 2/2017 Zur Ausgabe

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

06.05.2024 Kolonkarzinom Nachrichten

Menschen mit linksseitigem Kolonkarzinom leben im Mittel zweieinhalb Jahre länger als solche mit rechtsseitigem Tumor. Auch aktuell ist das Sterberisiko bei linksseitigen Tumoren US-Daten zufolge etwa um 11% geringer als bei rechtsseitigen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.